Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes

W. U. Kim, S. A. Yoo, S. Y. Min, S. H. Park, H. S. Koh, S. W. Song, C. S. Cho

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Inadequate apoptosis may contribute to the synovial hyperplasia associated with rheumatoid arthritis (RA). The Fas-associated death domain protein (FADD)-like interleukin (IL)-1β-converting enzyme (FLICE)-inhibitory protein (FLIP), which is an apoptotic inhibitor, has been implicated in the resistance to Fas-mediated apoptosis of synoviocytes. This study investigated whether hydroxychloroquine (HCQ), an anti-rheumatic drug, induces the apoptosis of rheumatoid synoviocytes, and modulates the expression of FLIP. Fibroblast-like synoviocytes (FLS) were prepared from the synovial tissues of RA patients, and were cultured with various concentrations of HCQ in the presence or absence of the IgM anti-Fas monoclonal antibodies (mAb) (CH11). Treatment with HCQ, ranging from 1 to 100 μM, induced the apoptosis of FLS in a dose- and time-dependent manner. The increase in synoviocytes apoptosis by HCQ was associated with caspase-3 activation. A combined treatment of HCQ and anti-Fas mAb increased FLS apoptosis and caspase-3 activity synergistically, compared with either anti-Fas mAb or HCQ alone. The Fas expression level in the FLS was not increased by the HCQ treatment, while the FLIP mRNA and protein levels were decreased rapidly by the HCQ treatment. Moreover, time kinetics analysis revealed that the decreased expression of FLIP by HCQ preceded the apoptotic event that was triggered by HCQ plus anti-Fas mAb. Taken together, HCQ increases the apoptosis of rheumatoid synoviocytes by activating caspase-3, and also sensitizes rheumatoid synoviocytes to Fas-mediated apoptosis. Our data suggest that HCQ may exert its anti-rheumatic effect in rheumatoid joints through these mechanisms.

Original languageEnglish (US)
Pages (from-to)503-511
Number of pages9
JournalClinical and Experimental Immunology
Volume144
Issue number3
DOIs
StatePublished - Jun 2006

Fingerprint

Hydroxychloroquine
anti-Fas monoclonal antibody
Apoptosis
CASP8 and FADD-Like Apoptosis Regulating Protein
Fibroblasts
Caspase 3
Synoviocytes
Rheumatoid Arthritis
Fas-Associated Death Domain Protein
Caspase 1
Antirheumatic Agents
Therapeutics
Hyperplasia
Immunoglobulin M

Keywords

  • Apoptosis
  • Fas
  • FLIP
  • Hydroxychloroquine
  • Synoviocyte

ASJC Scopus subject areas

  • Immunology

Cite this

Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. / Kim, W. U.; Yoo, S. A.; Min, S. Y.; Park, S. H.; Koh, H. S.; Song, S. W.; Cho, C. S.

In: Clinical and Experimental Immunology, Vol. 144, No. 3, 06.2006, p. 503-511.

Research output: Contribution to journalArticle

Kim, W. U. ; Yoo, S. A. ; Min, S. Y. ; Park, S. H. ; Koh, H. S. ; Song, S. W. ; Cho, C. S. / Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. In: Clinical and Experimental Immunology. 2006 ; Vol. 144, No. 3. pp. 503-511.
@article{cd8d4f80c5164cea8fa2d9d197acf9b0,
title = "Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes",
abstract = "Inadequate apoptosis may contribute to the synovial hyperplasia associated with rheumatoid arthritis (RA). The Fas-associated death domain protein (FADD)-like interleukin (IL)-1β-converting enzyme (FLICE)-inhibitory protein (FLIP), which is an apoptotic inhibitor, has been implicated in the resistance to Fas-mediated apoptosis of synoviocytes. This study investigated whether hydroxychloroquine (HCQ), an anti-rheumatic drug, induces the apoptosis of rheumatoid synoviocytes, and modulates the expression of FLIP. Fibroblast-like synoviocytes (FLS) were prepared from the synovial tissues of RA patients, and were cultured with various concentrations of HCQ in the presence or absence of the IgM anti-Fas monoclonal antibodies (mAb) (CH11). Treatment with HCQ, ranging from 1 to 100 μM, induced the apoptosis of FLS in a dose- and time-dependent manner. The increase in synoviocytes apoptosis by HCQ was associated with caspase-3 activation. A combined treatment of HCQ and anti-Fas mAb increased FLS apoptosis and caspase-3 activity synergistically, compared with either anti-Fas mAb or HCQ alone. The Fas expression level in the FLS was not increased by the HCQ treatment, while the FLIP mRNA and protein levels were decreased rapidly by the HCQ treatment. Moreover, time kinetics analysis revealed that the decreased expression of FLIP by HCQ preceded the apoptotic event that was triggered by HCQ plus anti-Fas mAb. Taken together, HCQ increases the apoptosis of rheumatoid synoviocytes by activating caspase-3, and also sensitizes rheumatoid synoviocytes to Fas-mediated apoptosis. Our data suggest that HCQ may exert its anti-rheumatic effect in rheumatoid joints through these mechanisms.",
keywords = "Apoptosis, Fas, FLIP, Hydroxychloroquine, Synoviocyte",
author = "Kim, {W. U.} and Yoo, {S. A.} and Min, {S. Y.} and Park, {S. H.} and Koh, {H. S.} and Song, {S. W.} and Cho, {C. S.}",
year = "2006",
month = "6",
doi = "10.1111/j.1365-2249.2006.03070.x",
language = "English (US)",
volume = "144",
pages = "503--511",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes

AU - Kim, W. U.

AU - Yoo, S. A.

AU - Min, S. Y.

AU - Park, S. H.

AU - Koh, H. S.

AU - Song, S. W.

AU - Cho, C. S.

PY - 2006/6

Y1 - 2006/6

N2 - Inadequate apoptosis may contribute to the synovial hyperplasia associated with rheumatoid arthritis (RA). The Fas-associated death domain protein (FADD)-like interleukin (IL)-1β-converting enzyme (FLICE)-inhibitory protein (FLIP), which is an apoptotic inhibitor, has been implicated in the resistance to Fas-mediated apoptosis of synoviocytes. This study investigated whether hydroxychloroquine (HCQ), an anti-rheumatic drug, induces the apoptosis of rheumatoid synoviocytes, and modulates the expression of FLIP. Fibroblast-like synoviocytes (FLS) were prepared from the synovial tissues of RA patients, and were cultured with various concentrations of HCQ in the presence or absence of the IgM anti-Fas monoclonal antibodies (mAb) (CH11). Treatment with HCQ, ranging from 1 to 100 μM, induced the apoptosis of FLS in a dose- and time-dependent manner. The increase in synoviocytes apoptosis by HCQ was associated with caspase-3 activation. A combined treatment of HCQ and anti-Fas mAb increased FLS apoptosis and caspase-3 activity synergistically, compared with either anti-Fas mAb or HCQ alone. The Fas expression level in the FLS was not increased by the HCQ treatment, while the FLIP mRNA and protein levels were decreased rapidly by the HCQ treatment. Moreover, time kinetics analysis revealed that the decreased expression of FLIP by HCQ preceded the apoptotic event that was triggered by HCQ plus anti-Fas mAb. Taken together, HCQ increases the apoptosis of rheumatoid synoviocytes by activating caspase-3, and also sensitizes rheumatoid synoviocytes to Fas-mediated apoptosis. Our data suggest that HCQ may exert its anti-rheumatic effect in rheumatoid joints through these mechanisms.

AB - Inadequate apoptosis may contribute to the synovial hyperplasia associated with rheumatoid arthritis (RA). The Fas-associated death domain protein (FADD)-like interleukin (IL)-1β-converting enzyme (FLICE)-inhibitory protein (FLIP), which is an apoptotic inhibitor, has been implicated in the resistance to Fas-mediated apoptosis of synoviocytes. This study investigated whether hydroxychloroquine (HCQ), an anti-rheumatic drug, induces the apoptosis of rheumatoid synoviocytes, and modulates the expression of FLIP. Fibroblast-like synoviocytes (FLS) were prepared from the synovial tissues of RA patients, and were cultured with various concentrations of HCQ in the presence or absence of the IgM anti-Fas monoclonal antibodies (mAb) (CH11). Treatment with HCQ, ranging from 1 to 100 μM, induced the apoptosis of FLS in a dose- and time-dependent manner. The increase in synoviocytes apoptosis by HCQ was associated with caspase-3 activation. A combined treatment of HCQ and anti-Fas mAb increased FLS apoptosis and caspase-3 activity synergistically, compared with either anti-Fas mAb or HCQ alone. The Fas expression level in the FLS was not increased by the HCQ treatment, while the FLIP mRNA and protein levels were decreased rapidly by the HCQ treatment. Moreover, time kinetics analysis revealed that the decreased expression of FLIP by HCQ preceded the apoptotic event that was triggered by HCQ plus anti-Fas mAb. Taken together, HCQ increases the apoptosis of rheumatoid synoviocytes by activating caspase-3, and also sensitizes rheumatoid synoviocytes to Fas-mediated apoptosis. Our data suggest that HCQ may exert its anti-rheumatic effect in rheumatoid joints through these mechanisms.

KW - Apoptosis

KW - Fas

KW - FLIP

KW - Hydroxychloroquine

KW - Synoviocyte

UR - http://www.scopus.com/inward/record.url?scp=33744470837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744470837&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.2006.03070.x

DO - 10.1111/j.1365-2249.2006.03070.x

M3 - Article

VL - 144

SP - 503

EP - 511

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -